|
Palo Alto, CA – September 17, 2008 – Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Wednesday, September 24, 2008 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). Telik’s presentation will be webcast live and will be available for replay through the Telik website, www.telik.com, through October 25, 2008.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA ®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA ®, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP ®, which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.
###
Contact:
Patricia P. Frias
Corporate Communications
Telik, Inc.
Tel: 650 845 7927
Email: pfrias@telik.com
Go to: 2008 Press Releases
2007
Press Releases
2006
Press ReleasesEvents |
TELIK ANNOUNCES PRESENTATION AND WEBCAST AT UBS GLOBAL LIFE SCIENCES CONFERENCE
